Javelin Pharmaceuticals Inc (JAV)

[surf1944]

Javelin Pharmaceuticals, Inc. Tops Up Balance Sheet Through Registered Direct Offering

Press Release
Source: Javelin Pharmaceuticals, Inc.
On 9:25 am EDT, Friday October 30, 2009

Companies:Javelin Pharmaceuticals, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (NYSEAmex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today received commitments from a single institutional investor, to purchase up to 3,186,700 shares of its common stock for estimated gross proceeds of approximately $3.9 million.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's web site at http://www.sec.gov, or from Javelin Pharmaceuticals, Inc., 125 CambridgePark Drive, Cambridge, MA 02140 Attention: General Counsel.

A shelf registration statement relating to the securities being offered has been filed with the Securities and Exchange Commission and has become effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.